Q2 2022 Avantor Inc Earnings Call
Good morning, ladies and gentlemen.
My name is Irene and I would be your conference operator today at this time I would like to welcome everyone to Ventas second quarter 'twenty to 'twenty two.
<unk> Conference call I will now turn the corner over to Christina Jones, Vice President of Investor Relations. Mrs. Jones, you may begin the conference.
Good morning, Thank you for joining us our speakers today are Michael Stubblefield, President and Chief Executive Officer, and Tom <unk> Executive Vice President and Chief Financial Officer, The press release and a presentation accompanying this call are available on our Investor Relations.
Web site at IR <unk> Sciences Dot Com a replay of this webcast will also be made available on our website after the call.
Following our prepared remarks, we will open the line for questions.
During this call we will be making some forward looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate may occur in the future.
These forward looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings.
Actual results might differ materially from any forward looking statements that we make today.
These forward looking statements speak only as of the date they are made we.
We do not assume any obligation to update these forward looking statements as a result of new information future events or other development.
This call will include a discussion of non-GAAP measures a reconciliation of these non-GAAP measures can be found in the appendix to the presentation with that I will now turn the call over to Michael.
Thanks P J and good morning, everyone. I appreciate you joining us today I'm starting on slide three.
As we announced in our press release, we delivered another outstanding quarter with strong results across all key financial metrics, including core revenue growth margin expansion earnings growth and free cash flow generation. Our results capped a strong first half of the year and highlight our exposure to attractive end markets, our differentiated product and service off.
Brings.
The resiliency of our business model and a dynamic macro environment and our continued track record of execution.
Continuing our momentum from the first quarter, we achieved six 4% core organic revenue growth on an 18, 4% comparable from a year ago, driven by continued strength in Biopharma and advanced technologies and applied materials. Once again, our core bio production business grew over 20% in the quarter and we're set up for continued growth.
<unk> order book, reflecting the ongoing strength of the biologics pipeline and our broad exposure to all modalities, we expanded EBITDA margins by over 140 basis points, including strong expansion in our core business and benefits from our 2021 acquisitions through.
Through the first six months of the year, our core organic revenue growth and margin expansion are tracking to our 2022 guidance and above our long term targets.
As we execute our operating plan. We also continue to progress our long term growth strategy through product innovation exciting new collaborations and ongoing capacity expansion projects in the second quarter, we launched new products in several areas, including J T Baker high precision consumables viral and activation solutions as well.
As a new line of Master flex pumps with an advanced user interface to support customer fluid transfer needs in both lab and production environments.
We also entered into collaborations with Gemini bio to provide plasma DNA inside of Ams to provide custom hydrated solutions and cell culture media to Biopharma customers with these collaborations we have expanded our bio production offering and enabled our customers to utilize custom cgmp products through the full development cycle.
<unk> early stage research scale up and commercialization.
We have several capacity expansion projects in flight and recently started construction in our Phillipsburg, New Jersey manufacturing site to.
To significantly increase our global capacity for process ingredients to support growth in our bio production platform.
Our M&A integrations remain on track and we achieved several critical milestones for mast reflects this quarter, including successfully executing on our planned ERP implementations in Europe , India and China at this point all ERP integrations outside of the Americas are complete and we remain on schedule to wind down all TSA before year end <unk> is now integrated.
Into our portfolio and we remain focused on executing on new product launches and commercial synergies looking ahead, we have good momentum in our end markets. Our order book is strong and we continue to leverage the of onshore business system to drive execution in a challenging operating environment, we remain confident in delivering another year of strong financial results.
Given the dynamic macro environment, we thought it would again be helpful to provide a brief update on some of the factors impacting our space and how we are leveraging the onshore business system to manage through these challenges.
Starting on the left side of slide for the global economy has become a bit choppy or with slowing GDP growth tighter financial conditions and the ongoing geopolitical conflict in Ukraine.
Despite these headlines we continue to see strength in our end markets.
Notably in the second quarter, we experienced more than 20% core organic growth in our bio production business and strong growth in our semiconductor platform that drove double digit growth in our advanced technologies and applied materials end market.
The order books for our proprietary businesses remained strong highlighted by bio production and bio materials, where we have nearly a full year of demand on order.
Moving to foreign exchange U S. Dollar has strengthened considerably against most currencies since the beginning of the year. This presents incremental foreign currency translation headwinds for the roughly 40% of our business outside the U S. In the second quarter FX was a four 4% headwind to reported revenue and impacted earnings per share by approximately <unk> <unk>.
Based on the expectation of the US dollar will remain strong through the balance of the year.
We have updated our full year EPS guidance to reflect this impact regarding interest rates, our financing structure and strong free cash flows have enabled us to maintain our 2022 interest cost at the originally forecasted level. Despite the escalation in U S. LIBOR and Euribor indices. We also expect interest cost reduction in 2023 and beyond as we.
Continuing to Delever and we have no significant required debt repayments until 2025.
Covid headwinds increased in the second quarter to approximately 4% looking ahead, we expect full year COVID-19 headwinds of around 3%, reflecting approximately $100 million less COVID-19 related revenues than planned at the beginning of the year as vaccine related revenue is moderating faster than anticipated, we expect our core bio production business to offset this.
Incremental headwind as we redeploy production capacity and we are maintaining our full year guidance for <unk> of mid single digit organic growth.
We are encouraged by the recent improvements in China activity levels. However, the strict lockdowns in the quarter did create a roughly 50 basis point headwind to our top line results. Excluding this headwind our EMEA business grew high single digits on a core organic basis in the quarter.
While inflation continued to impact nearly all our cost categories. We delivered over 140 basis points of margin expansion in the second quarter and first half you've onto our business system is helping us deliver commercial excellence and productivity and together with the favorable impact of our 2021 acquisitions. Our first half margin expansion is above our 2022.
Full year guidance of 125 basis points and above our long term algorithm of 50 to 100 basis points per year, a final point on supply chain. The global supply chain has been constrained since the start of the pandemic for example in the second quarter, we faced printed circuit board and resin shortages, which impacted our single use revenues we can.
To leverage our global network to mitigate episodic supply chain issues and expect modest improvements over the course of the year, we remain confident that our investments across the network will enable us to continue to improve service levels and shortened lead times.
While the macroeconomic situation is challenging the resiliency of our business model and our track record of execution give us confidence in serving our customers and delivering strong financial performance.
Moving to Q2 performance on page five second quarter core organic revenue growth was six 4% on top of an 18, 4% growth comparison from the prior year adjusted EBITDA in the quarter was up 10, 2% driven by commercial excellence, a stronger weighting our proprietary offerings and the favorable boost from our 2021 Act.
Physicians.
Our strong operating results drove adjusted net income growth of 11, 1% in.
37 of adjusted earnings per share this quarter, we generated free cash flow in excess of $190 million in the quarter, while continuing to ramp investments in the business to support our growth our adjusted net leverage of three nine times adjusted EBITDA is in line with our two to four times target leverage supporting our ongoing focus on building a robust M&A pipeline.
With that let me turn it over to Tom to walk you through our financial results in more detail.
Thank you Michael and good morning, everyone I'm, starting on slide six building on Michael's comments, we generated total revenue of $1 $91 billion in.
In the second quarter, representing a two 8% reported growth rate.
Our underlying core organic growth rate, excluding COVID-19 headwinds was six 4%. Despite the challenging 18, 4% comparable over the last three years, we've averaged five 8% core organic growth in the second quarter, which is at the high end of our 4% to 6% long term target or.
<unk> related headwinds were higher this quarter coming in at four 1% Covid vaccine related revenues are moderating faster than anticipated and we now expect COVID-19 related headwinds of approximately 3% for the year you will see in a minute that we expect to offset these higher COVID-19 headwinds with core growth and are maintaining our full year organic.
<unk> revenue growth guidance.
Our 2021 acquisitions increased our revenues by four 9% more to come on this in a minute and the stronger U S. Dollar created foreign currency translation headwinds of roughly four 4% on to page seven.
On a regional perspective, Americas, which represents approximately 60% of annual global sales achieved an eight 1% core organic revenue growth driven by continued strength in biopharma and advanced technologies and applied materials within Americas Biopharma, our bio production business grew more than 20% on a core organic base.
This.
With strength across process ingredients excipient single use and serum.
Reflecting our strong research environment, our Biopharma R&D revenues were up high single digits, driven by strength in lab chemicals and equipment and instrumentation within advanced technologies and applied materials double digit sales growth was driven by our proprietary offerings to semiconductor and electronic device manufacturers Europe , which.
Resents approximately 35% of annual global sales achieved four 7% core organic revenue growth. Despite a challenging economic climate across Europe underlying demand remained strong.
Proprietary materials grew high single digits outpacing growth in all other categories.
Production grew over 25% in the region driven by demand for our process ingredients excipient and single use solutions.
Advanced technologies and applied materials grew low single digits, driven by strong sales of equipment and instrumentation EMEA, representing approximately 5% of annual global sales declined 3% on a core organic basis with Lockdowns in China impacting sales for the quarter, excluding China EMEA core organic sale.
<unk> increased high single digits.
<unk> technology and applied materials sales grew double digits, driven by sales of our proprietary offerings for the semiconductor industry and strong industrial demand in the region.
Slide eight shows our core organic revenue growth for the quarter by end market and product group.
Biopharma, representing almost 55% of our annual revenue experienced high single digit core organic growth in the quarter.
Including more than 20% core organic growth and by our production.
Our strong order book for proprietary offerings reflects a healthy bio production pipeline across maps cell and gene therapy, and mrna with attractive end market dynamics and incremental capacity coming online over the course of the next 18 months, we expect continued momentum in this business.
Health care, which represents approximately 10% of our annual revenue declined low single digits on a core organic basis in the second quarter against the more than 30% growth comp from last year.
The growth in our medical grade silicone offerings was offset by declines in third party offerings and part relating to supply chain challenges. We expect this end market to return to growth as comparable as moderate in the second half of the year and expect continued strength from biomaterials given the strong order book for our proprietary silicon offerings.
Education, and government, representing approximately 10% of our annual revenue experienced a low single digit core organic revenue decline in the second quarter and like health care was up against the challenging comp of nearly 40% in 2021 that included project related spend which is not repeated we expect.
And market to also returned to growth in the second half.
Advanced technologies and applied materials, representing approximately 25% of our annual revenue achieved double digit core organic revenue growth in the second quarter driven by growth of proprietary materials to semiconductor and electronic device customers by product group proprietary materials and consumables offerings achieved double digit core organic.
Revenue growth driven by strong demand for our process ingredients chromatography resins, excipient single use solutions and serum as well as for our electronic chemicals platform.
Sales of third party materials, and consumables increased mid single digits, reflecting broad chemicals and consumables demand across our end markets equipment and instrumentation sales remained strong in the quarter and services grew low single digits, reflecting strong demand for clinical services offset by reduced spend on specialty procurement services.
Let me turn to slide nine to offer some perspective regarding our other key financial performance metrics.
Michael previously mentioned the 10, 2% growth in adjusted EBITDA were about 14% without the foreign exchange translation headwinds to 21, 2%, reflecting expansion of our core business and contribution.
Core margin expansion was driven.
Driven by commercial excellence and favorable.
Sales of our proprietary materials and consumables.
These.
Positive factors were partially offset.
By increased cost of materials and freight as well as investments in our workforce made over the course of 2021.
Per share in the second quarter was 37.
And adjusted net income was up approximately 11% or closer to.
The 15% when adjusted for FX free cash flow in the second quarter was $191 million.
Higher capital spending to support.
For our growth higher interest relating to the 2021 acquisitions and increased income tax payments as a result of higher pretax income and timing turning to slide 10 I wanted.
Physicians, we deployed approximately a $4 billion for M&A in 2000.
Acquisitions of Ritter and masterfully.
Legacy platform these businesses.
Vacation driven revenue profile.
Got it.
Expand our proprietary offering to the Biopharma and health care end market. This is our second full quarter with master flex in the portfolio.
And the integration is progressing on track, including our recent ERP cutover in Europe , and EMEA and excellent traction on cost synergies the.
The demand for the Master Flex offering is strong we continue to collaborate with our biopharma customers and the order book is grow X from the China Lockdown.
Most notably printed circuit boards for apparel.
First off a pump offerings and resin based materials for the two.
Greater business is fully integrated into <unk>.
Our portfolio and we are excited to provide these high precision liquid handling consumables alongside our existing offerings for diagnostic and drug discovery applications.
Video revenues were less than anticipated in the quarter.
Driven by continued foreign exchange headwinds and Covid related declines we can continue to focus on executing our commercial synergy pipeline, which leverages. The advance of our distribution channel to create an aftermarket stream of revenues for this traditionally OEM focused business.
The lead time for this transition is considerable as the products must be formally approved and specified by our customers.
An extensive sampling testing and qualification protocol.
We also continued to invest in expanding the product line through new product introductions to leverage <unk> capabilities as our high precision consumables center of excellence.
Our opportunity pipeline continues to progress and we remain confident in achieving the targeted returns on this investment we have incorporated these developments into our full year 2022 expectations and are now forecasting over $450 million of revenue greater than $155 million of adjusted EBITDA and more than <unk> of earnings per share.
Sure.
Organic growth and expanded adjusted EBITDA margins by approximately 100 grew adjusted net income by about <unk>.
Teen percent, resulting in 75 of adjusted EPS.
In the first half of 2022, given ongoing business momentum and less aggressive comparable growth in the second half, we anticipate modestly stronger core.
Organic growth rates in Q3, and Q4 and attractive margin expansion in line with our original full year guide.
Our 4% to 6% organic revenue growth guidance remains intact.
Including Covid headwinds of 3%, we expect to deliver core organic revenue growth of 7% to 9%. We are encouraged by healthy demand pattern.
In our core business.
Got it.
Adjusted EBITDA, we anticipate continued commercial and operational execution.
Execution in an attractive way.
Getting a higher margin proprietary offerings, including those in bio production.
We are updating our adjusted EPS.
EPS range to $1 four.
Principally reflecting foreign exchange translation headwind as well as the updated outlook.
We have modestly reduced free cash flow to reflect these factors.
This concludes my prepared remarks.
Remarks, I will now hand, the call back to Michael.
Thanks, Tom Im now on slide 12.
We delivered another solid quarter with strong results acquirements I remain encouraged by resiliency of our business model and our.
Once and productivity initiatives.
Such an expansion the integration of our 2021 acquisitions is progressing well and we're excited about the growth potential of our combined portfolio.
So given the continued momentum of our business and ongoing deleveraging, we continue to actively build our M&A pipeline.
Look forward to her contributions in helping us shape and execute our enterprise growth strategy in May we released our 2022.
Two sustainability report, which highlight significant progress across of Entre for ESG priorities as a company focused on advancing science to create a better world. We recognized for all our stakeholders and we remain committed to delivering our sustainability goals.
I want to thank you for your interest in <unk> and for your ongoing support.
I will now turn it over to the operator to begin the question and answer portion of our call.
Ladies and gentlemen, we will now begin our question and answer session to ask a question.
One on your telephone keypad now.
Your question. Please press Star then two.
If you are before pressing the keys.
The interest of time, we ask that.
One question only.
Yes.
Yes.
Media participants it seems like we have lost connection with our.
Speakers.
Please bear with us until later.
The nexsan.
Alright.
Okay.
[music].
Sure.
Okay.
Okay.
Okay.
Sure.
Sure.
Okay.
Okay.
[music].
Okay.
Okay.
Good morning.
Okay.
Sure.
Okay.
Yes.
Okay.
Sure.
[music].
No.
Okay.
Sure.
Yes.
Dear participants our speakers have joined back off.
And we can now.
Take our question and answer session.
Our first question comes from Vijay Kumar from Evercore Lee J. Your line is open.
Hey, guys. Thanks for taking my question I have a two part question.
I think there's some confusion or not acquisition revenues they were cut from 500 <unk>.
There were two different numbers, there was a $90 million acquisition contribution in the slide deck had a $100 number.
Can you reconcile the 90 versus 100.
And then some.
500, <unk> how much of this is FX.
With massive flex revenues cut down and I think related to that.
Michael to you I mean, the stocks right now like 13, 14 currency forward EBITDA pricing in a massive growth slowdown for net share with us any sensitivities variables, we need to be aware of.
When we think about 20 states of comps.
Is it any slowdown in customer activity economic activity any comments would be helpful.
Yeah. Thanks P J.
As Tom and I apologize for the technical difficulties.
Thank you for your patience.
Yes.
Ill just tell you that.
$102 million.
And that we show in the slides is the Q2 revenue.
From rim.
Greater and Master flex.
You look at the 10-Q, which will be out shortly.
You'll be at we disclosed Q2 revenues are both ribbon later.
Sorry for both $1 billion.
Our remaining the remaining portion up to the 102.
Okay.
Well as.
Revenue.
Channels and not through.
Master flakes or so.
So again I can.
I understand why.
It wasn't clear.
The press release tables that show the $90 million.
That really is it.
Our year over year growth.
From the from last year's starting point.
It does.
Revenue for the acquisition.
That excludes organic growth.
But the bulk of the timing of those acquisitions.
Okay.
Organic year over year, so hopefully that clarifies.
But again.
Thank you Michael is kind of touch on I will take the second part to your question there.
No.
The work.
The 500 that we had previously for M&A down the $4 50.
Both factors there as we noted on the call were.
Certainly FX.
Well as stronger.
Covid headwinds.
And rolls up to.
Certainly higher than we.
You take Master Flex for example, we actually have.
Demand.
Sure.
Our original plan.
And maybe being a bit conservative here.
Good morning.
Take.
An aggressive stance on how the supply chain constraints might play out in the second half that it would be prudent to be a bit.
And we're really encouraged by the momentum we have.
I have in our pipeline we have several thousand.
Opportunities.
Further progress of qualifying.
And as that end market adjusts from.
The COVID-19 focused at a tad.
2021 to a more normalized.
Environment with more normalized inventory levels, we're confident we're going to see the growth going forward.
As we think about 2023, obviously a bit early for us to speculate on how that might turn out.
We're operating.
Operating in a pretty choppy macro environment at the moment with a lot of things.
Moving around.
Whether it be FX or inflation.
Certainly Jim.
Okay.
You can see from our strong.
Core growth in the quarter.
That gives us any signals that we're headed for.
Yeah.
In an environment that would deteriorate.
Yeah.
Thank you.
Forward to understand about our business is very resilient.
The storms.
The marketplace.
From time to time, we have our consumables.
Got it and.
Has performed historically well.
Through the previous day.
Downturns.
And since those downturns I would say that the quality of our business has improved substantially when you look at the percentage of our revenue is exposed to biopharma.
None of our revenue that specced into production platforms.
We're starting from a position straightened here with a lot of momentum.
Thank you.
Our next question comes from Dan Brennan from Cowen Ben Your line is open.
Great. Thanks, Thanks for taking the questions Michael.
Michael and Tom.
So like a voluntary stock has been penalized in the past maybe for a lack of clarity on maybe some specific guidance items, so maybe with that in mind.
We hope to ensure like we understand the kind of how we think about the pacing of revenues in the back half of the year, namely could you just give us some perspective Q3 Q4, how we should think about COVID-19 inorganic growth on the core plus EBITDA margins and free cash flow pacing and maybe connected to that.
Maybe give us some color on what your visibility is like towards the back half of the year in terms of you talked about your backlog.
And what if anything you are baking in for weakened weakening economy. It sounds like youre not seeing anything yet so perhaps there's nothing really baked in thank you.
Thanks for the question Dan.
If you go back to what we've said.
And we indicated that our core organic revenue growth would be.
<unk>.
You see the results here I think we delivered on.
Okay.
I refer you back to Tom.
Our prepared comments.
By holding our full year organic guide at 4% to 6%.
Okay.
We're we're trending right in the middle of that through the first half of the year, you will see second half kind of playing out.
<unk> headwinds.
In the third and fourth quarter compared to say maybe in the first quarter.
Going to see modestly.
Please stronger.
Core organic growth in the third and fourth quarter principally weaker.
Year over year Comparables.
And in the fourth quarter were sitting at about 140 basis points of margin expansion at the midpoint.
And with our guide.
Coming in about 125 for the full year basis.
I think I would say Q3, and Q4 playing out of Opex, we saw the first half year to get us above our guidance.
Looking at.
Visibility.
Probably a couple of different ways I think about that.
Firstly on our proprietary offerings with respect into.
Our customers' production platforms, whether that be in production or inbound materials medical devices or EBIT.
EBIT in things like the semiconductor end market.
Our reporter bookstore.
The demand on order so we have.
Oh <unk>.
Great.
Visibility into that part of our business in the production part.
Part of our business structure behind units is roughly 40% of our overall revenues.
On the land portion of our of our business.
Where are we.
Principally leverage our.
Strong customer access and global footprint.
Service a customer base that is.
Quite agile.
And that most of the revenue that we generate areas.
Ordered and shipped within 24 to 48 hour period, so that business runs more on a momentum basis and become a daily rate of sales.
Basis here, but the momentum is good certainly as we progress through the second quarter.
Momentum improve.
Sitting here today, having.
Nearly finished the first month of the quarter that momentum has continued into the third quarter.
Thank you Sue.
Our next question comes from <unk>. Your line is open.
Hey, guys. Thanks for the questions here two two parter from me first one.
One on pricing so.
Michael I guess over the comps precision you were talking about and from last quarter that you werent able to get the full pricing.
From <unk> and that would basically bleed into <unk> and the rest of the year and so that's what we were looking for a step up sequentially here from growth and just kind of.
And talk about how that played out in the quarter.
Are you able to get as much as you were expecting or did some of that get pushed out.
How that impacted volume.
Volumes essentially.
What was the volume offset and then the second part here.
Can you talk about the underlying growth within master flex with.
With the $50 million guide down everybody.
Kind of a little skittish on that so they want to know how that's been growing I know you gave some some color on the order book there but.
Should we see extra upside here in case that the supply chain releases and those components sourcing that you guys sell through that channel is that is that source of upside just give us some sense here where that can go.
Yes, thanks for the questions on the pricing front I think the second quarter played out in line with how we had anticipated.
And you are correct in that.
The proportion of our orders in the second quarter that we satisfied.
At current pricing relative to.
The first quarter certainly.
Up in the pricing that we put into the marketplace.
Played out as we had anticipated and that was in part.
Reflected in the strong core organic growth that we that we delivered.
Of course, the offset at the organic line and is the stronger COVID-19 headwinds will be realized in the quarter.
In the first quarter Covid headwinds for roughly 2% and they stepped up.
Against the strongest Colgate <unk>.
Tailwind that we had in 2021 to about 4% four 1% headwinds.
With very little contribution from PPE.
Significantly.
Decline in contribution from.
From Covid testing Republic.
A quarter of what we were.
In the first quarter, and then vaccine starting to moderate.
Meaningfully as well.
So net net contributions from pricing playing out as anticipated strong underlying demand fundamentals, helping us achieve stronger core organic growth to offset the stronger COVID-19 headwinds.
Unmatched reflects we remain super excited that businesses essentially performing.
As well.
As our legacy businesses, such as you've seen we've been printing.
On a core basis more than 20% growth for bio production over the last number of quarters and as this quarter was no different.
Specific to mass reflects great order book.
Similar to our own.
As I indicated on one of the previous questions. We've got line of sight to the original.
Demand plan behind our original guidance.
Certainly there was some impact from China, there is a bit more exposure.
In China for that business that maybe our legacy business.
And there were some unique.
Apply chain constraints things like printed circuit boards that we don't face in the rest of our of our business. So.
Depending on how those things play out how much of the China demand recovers.
No.
See some relief from.
From the supply chain constraints, we certainly have the demand.
To deliver something stronger than what we've what we've signaled here.
Thank you. Our next question comes from Rachel VACMAN stall from J P. Morgan.
Your line is open.
Hey, Thanks for taking the question.
Here on radar first is really housekeeping just to follow up Jay Jays question. So radar closed intra quarter during Q 'twenty. One. So can you just confirm for us that difference between the PRN. This slide was that $90 million referenced in our press release reflected the inorganic M&A contribution during the quarter and then the slides that showed the one that really that total contribution.
M&A, which included <unk> <unk>.
Benefit from greater that's now listen to organic.
And then secondly, guiding a little bit deeper in greater thought to Luke's question. So can you just walk us.
And the numbers there how much of a headwind with FX and then separately really how much of that with Covid rollout.
And do you still expect to hit that high single digit core organic growth for radar.
Yes, great questions, Rachel Let me, let me take those.
Your.
Commentary there on the 90 versus the one or two was spot on.
Good understanding goods good explanation there it's really just the difference between.
What was reported last last June is inorganic and what we're now showing as inorganic now that we've lapped the one year milestone there some of that is starting to be shown as organic.
<unk>.
The reconciliation here.
Challenging to try to allocate the various factors that we've outlined here to get back to the $4 50, principally given our internal plan actually rolls up as we've indicated to something stronger than that Theres, obviously been some noise around the numbers here over the last couple of quarters, we're trying to be a bit cautious here and.
Yes.
Put out.
Maybe a conservative guy.
Guide here so.
We can put the focus on.
The long term outlook for this business, which continues to be very robust specific to reenter.
The core business continues to grow high single digits.
Plagued by even stronger.
Covid headwinds and what we can understood, it's probably more in the range of 20% to 25% of revenues.
Jumping off points are proving to be.
Somehow linked to Covid and given our business is principally denominated in euros given its legacy.
That business is being disproportionately impacted by FX compared to the rest of our of our business.
When you look at the synergy plan, which is really where our focus is.
We're on track to deliver our year one synergy plan.
For 2022 now.
Now given that the headwinds of Covid, where obviously, we're hopeful of trying to pull ahead. Some of our 2023 synergies into the year and we're just facing the practical realities of.
There is a.
A specific timeline that needs to be followed here as you qualify these products with your with your customers.
As well as the reality that there is a bit.
Over inventory overhang in the channel just given the drop off in.
And COVID-19 testing, but the opportunity pipeline looks great again, several thousand opportunities. We've got great traction, we're going to hit our synergy plan for the year end.
We are.
Alongside that.
Resolutely expanding the product portfolio, we've been making investments literally from day, one that will roll out over the course of the.
This year and into next year in my prepared remarks, I mentioned some of the J T Baker branded.
Consumables that we launched in the quarter those are coming from from Ritter. So.
A lot of momentum there the core is in great shape, we're super excited about the capabilities that we have here.
Remain confident in the long term.
Potential of this business.
Thank you. Our next question comes from DHS Pavan <unk> from Morgan Stanley .
Your line is open.
Hey, guys. Good morning, and thanks for the time here two parter from me one on Covid and then I've got a follow up on on the tuck ins So an oncall that.
Michael and Tom I mean can you share some color on what you're embedding in the second half outlook in terms of <unk> I know you mentioned seeing.
Bit of a moderation, but tighter earlier and now Madonna overnight, both announced large U S government orders.
Would that potentially lead to a little bit of upside here that I can understand why you want to be prudent about how you frame the outlook and then on the M&A piece. This is more of a philosophic.
Philosophical question really I mean.
In terms of some of the issues here.
<unk> been largely sort of factors are beyond your control, including Covid in the supply chain.
Are there any sort of like key learnings.
From the past 12 months that you'd like to flag.
Any implications from that on a go forward basis in terms of either.
Perhaps some near term breather on the deal front or how you approach forecasting and integration next time around.
Yes, thanks for the questions on on the Covid vaccine front.
Things have moderated.
Youll, probably quicker than what we would have anticipated coming into the year and that is the principal driver for <unk>.
Why we were maybe early in the year thinking about.
Something closer to.
$250 million of.
Covid related revenues and we're now signaling at a 3% headwind something close to $150 million.
A big part of that if not most of that is certainly.
Take down in the in the vaccine contribution from.
From the from the year.
And Thats really backed by our discussions with our customers. The order books that we that we have and the.
The work we're doing to.
Transition some of that capacity too.
Two our core business so to the extent that there is another massive wave of.
A vaccination.
I Wouldnt say that its necessarily reflected in our in our current.
Order book.
To the extent that were to play out perhaps you could provide some upside but we don't we don't have line of sight to that as we as we sit here today relative to M&A as we've said.
Super excited about the capabilities that these acquisitions have brought to us.
I think it strengthens our platform and certainly the feedback from our customers has been really terrific and the traction we're getting on synergies.
Yes.
Yes.
Expected.
The macro environment is injected a bit of noise into into the results.
Here that we're facing and fortunately the.
The benefits of the acquisitions, principally the core organic growth and margin expansion from these deals you can see the impact of those things.
On our on our business.
As I indicated in my prepared remarks.
<unk> hired a new head of corporate development and strategy, which.
We're super excited to have her onboard.
She brings a really deep background across.
A lot of our end markets, including Biopharma.
And a tremendous amount of.
We'll experience over the last couple of decades.
With the balance sheet, where it's at we remained active in continuing to build that.
Pipeline.
We would still.
C.
Our principal capital allocation.
Strategy.
Continuing to Delever and.
The opportunistic here as we think about.
M&A.
Okay.
Thank you. Our next question comes from Mac Sykes from Goldman Sachs. Matt Your line is open.
Great. Thanks for taking my questions good morning, Mike.
My first question is just on.
The Covid vaccine.
Revenue telling.
Telling off faster than you expected, how fungible is that demand, meaning given your strong order book, where every year worth of orders are.
Are those customers maybe at the same customers or new customers looking to secure that freed up capacity as Copa comes down so meaning can you just translate that capacity.
Into your order book or is there a period of transition that needs to take place.
Within bio production for that to happen.
Matt one of the things, we really like about our <unk> and some of the new and emerging therapies of cell and gene therapy and mrna is as we've seen here.
And colon vaccines.
So in many cases.
The infrastructure and the products are are the same and so.
Throughout the pandemic.
We've actually been.
On a daily basis, and sometimes even an hourly basis.
These lines are modulating from producing.
Covid and non Covid solutions, so to that extent.
It's almost instantly.
<unk> here.
Probably the one governor as to at a moment in time, how fungible. It can actually be is is just the scheduling of raw materials for the specific orders youre trying to satisfy.
Which could inject a few weeks to a few months delay on some of those orders, but generally we view it to be quite fungible and as you look at our core organic print here on bio production.
Well over 20%.
Again, I think we're doing a really nice job of.
Kind of winding down the support for the for the vaccines and ramping.
Satisfaction of our core order book, which again remains extremely.
Robust so we're certainly.
Driving core growth well ahead of the market growth, there, which I think is another proof point for you on the success, we're having in.
Maximizing capacity utilization.
To meet the demand for our for our customers.
Thank you our next question comes from.
Mike from Keybanc.
Your line is open.
Yes, Michael I guess.
We're talking <unk>, you have a year back log in bioprocess.
I think the summary is that the supply chain is.
Limiting it to a certain degree how quickly you can deliver that is that a fair way to say it but you are still at the same token growing above market is that the right way to think about it.
In our bio production business no doubt we continue to outpace.
And take share in the marketplace, and we view ourselves as the leading materials supplier.
Pretty attractive and robust space for them to do more than that certainly there are supply chain issues and I don't want to you can.
Maybe put two Brian a spotlight on this we've had some <unk> issues in years and throughout the pandemic they might move around a bit in terms of where the hotspot happens to be at any moment in time, but as you saw from.
Supply chain.
Aggregate.
As was probably somewhat of a portion in the quarter.
But certainly there.
How material constraints.
Preventing doing even even more in bio.
While production, but you also have the practical reality.
Customers for these things.
Yes.
<unk>.
There is a limit to how early.
To access these materials.
Okay.
They need to be stored in <unk>.
Controlled environments and so there is some practical limitations.
As to how much of the demand you can you can pull forward.
Customers are interested in getting product in advance of their.
Cycles.
Right.
Okay.
Excited for me to ship at six months early for example.
Thank you our next question.
From a nephron research Jack Youre line is open.
Okay.
Thank you good morning.
Michael There were some questions coming in.
And the channel with customers was curious to get your thoughts on just how much visibility you have into this.
As it relates to that.
Yes, I think our view today is still consistent what we said before Jack in that we don't have.
Line of sight.
Meaningful inventory.
There is certainly going to be the one off category, our customer here that would be the outlier.
As as there always is but.
We have a pretty interesting seat at the table and a lot of our customers.
Matt and me.
Many cases.
Through our service offerings that are managing.
Stock rooms in England.
Oregon and managing that.
As the supply chain.
And certainly there is there is no signals coming from from that population that would indicate that our customers are intentionally trying to build.
Inventory and then on the production side.
Of our business.
Theres just a lot of practical.
Strengths that would keep our customers from building meaningful amounts of.
Inventory, including storage space and the fact that these things have to be stored in a controlled.
Environment, and there are shelf life considerations that need.
To be accounted for so.
As we sit here I don't think we see inventory you don't feel this is a particular concern.
Thank you.
Our next question comes from Michael <unk> from Bank of America Michael.
Michael Your line is open.
Great. Thanks. This is Mike on for Derek Brown.
Want to follow up on some of the Covid questions can you go into a little bit more detail of how much is COVID-19 three.
A 3% headwind for the year it looks like you're kind of assuming a similar run rate to Q3 Q4 Q1 COVID-19.
Is that sort of the baseline level going forward is that.
Is that de risked for next year or is there a chance of another COVID-19 headwind to revenues next year as we tried to sort of reconcile that 4% to 6%.
Underlying and.
Mike did you have a second question tubes, I don't want to get cut off before you get it in.
Okay.
Thanks for the question, Yes, I think you have it right when we entered the year.
Coming off 2021, when we had about $400 million of.
Covid related revenue about half of that was a vaccine related and the rest was split between <unk> and diagnostic testing.
As we look at our latest well our.
Our initial guidance was that.
We saw.
About 2% overall <unk>.
Impact organic growth. So the 400 would come down to call it $2 50.
We've just based on the trending in the first quarter and second quarter.
We're seeing that additional 100 come out so by the end of it.
Revenues for.
For the full year 2022.
Okay.
I would characterize that is that the absolute maximum.
<unk> for 2023.
Because again this was built on.
Specific.
Revenue offerings in those three categories.
That I mentioned.
And so once they are fully exhausted once that revenue is fully exhausted.
You are at.
We're at a point, where you are everything is organic and there is no difference going forward hopefully that helps and I think it's also important to remember that that that $400 million or so.
Covid revenue last year it was.
First half versus second half the comparisons were.
Pretty enormous we had.
<unk>.
Close to.
230 to $2 50 of it the first half.
Nadir of the second half.
The COVID-19 comps in the second half.
To begin to moderate a bit.
And Thats.
We think 4% headwind is probably the high point for the year.
For the year.
Will average out to 3%.
Sure.
Thank you.
Our next question comes from Patrick Donnelly from Citi.
Your line is open.
Hey, guys. Thanks for taking the question.
Two part and Tom maybe just to follow up quickly kind of touched on it there when we think about the second half organic.
Thank you guys good about three and a half a little more in the first half obviously the guidance stands for four to six is that second half.
Is that mainly just that COVID-19 piece easing you can talk about there quickly and then second just on the M&A strategy, Michael you touched on earlier how.
How are you guys balancing.
The absolute revenues and quantum of <unk>.
Revenues in the third and fourth quarter for.
For Coke those COVID-19 related offerings it in 'twenty one.
Had moderated as we had disclosed so the comps get a little bit.
At a more moderate as Michael said and so the impact on organic growth.
Is more limited, but we've got that factored into the into.
And to the guide we do think Q3 picks up.
Even on a on a core organic basis.
<unk>.
Covid headwinds.
In the fourth quarter as well.
So.
That's what we baked into.
The updated guidance and Patrick on your second question regarding kind of M&A strategy.
Continue to Delever in line with our expectations with the deleveraging in the quarter. We're now within the two to four times target leverage.
Quite purposely we.
Finance the mass reflects acquisition was a bit of equity to preserve.
Flexibility and Optionality.
We can participate if the right deal came along obviously.
A little bit of a muted M&A environment right now with <unk>.
I'll be a pretty big gap between buyer and seller.
Greg patients right now.